solute carrier family 7 member 1Genealiases: ATRC1 · CAT-1 · ERR · HCAT1 · REC1L
Q-omics provides the consensus-scored SLC7A1 profile across patient tissues and cancer cell-line models. SLC7A1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC7A1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SLC7A1 protein abundance shows 25,065 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where SLC7A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC7A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC7A1 survival associations across molecular data types. SLC7A1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC7A1 RNA expression–survival associations across cancer types. High SLC7A1 expression shows unfavorable associations in KIRP, ACC, CESC, UVM, LIHC and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC7A1 RNA expression.
This table summarizes SLC7A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC7A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC7A1 shows lower tumor expression in THCA and higher tumor expression in COAD, STAD, LUSC, LIHC and LUAD. The COAD box plot shows higher SLC7A1 RNA expression in tumor versus normal tissue (log2 FC = +1.865, t-test p < 0.001).
This table shows molecular features associated with SLC7A1 in patient tissues and cancer cell lines. In patient samples, SLC7A1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC7A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
